A Case of Acquired Methyamalonic Aciduria Secondary to a Subclinical Maternal Pernicious Anaemia

Stuart Gallacher1*, Helen Prunty2, Alison Jones2, Robin H Lachmann3 and Paul Gissen2,4

1University of Edinburgh, College of Medicine and Veterinary Medicine, UK
2Great Ormond Street Hospital for Children, UK
3Charle's Dent Metabolic Unit, National Hospital for Neurology and Neurosurgery, UK
4UCL Institute of Child Health and MRC Laboratory for Molecular Cell Biology, UK

*Corresponding author: Stuart Gallacher, University of Edinburgh, College of Medicine and Veterinary Medicine, Royal Infirmary of Edinburgh, 47 Little France Crescent, Edinburgh EH16 4TJ, UK, Tel: 44 131 242 9300; E-mail: s0806635@sms.ed.ac.uk

Abstract

Inherited methylmalonic acidurias are a group of autosomal recessive disorders caused by mutations in the genes encoding methylmalonyl CoA mutase and proteins involved in cobalamin (Vitamin B12) metabolism. Methylmalonic aciduria can also arise as a result of severe cobalamin deficiency. We report the case of a male infant presenting at 5 months of age with a cobalamin sensitive methylmalonic aciduria, pancytopaenia, developmental delay, failure to thrive, hepatosplenomegaly and hypotonia. MRI brain imaging showed reduced white matter quantity and maturity. The cause was investigated and discovered to be a maternal subclinical pernicious anaemia. A rapid clinical improvement was made upon initiation of B12 supplementation. At follow up aged 18 months weight was above the 91st centile and height between the 75th and 90th. Although no delay in fine motor or social skills was noted at 18 month assessment, gross motor and language delay persisted and may reflect central nervous system damage due to the initial B12 deficiency.

Methylamalonic aciduria is relatively frequently detected in patients with lack of dietary B12. If careful assessment of the diet does not provide the answer, it is important to perform laboratory investigations even if no clinical signs or symptoms of pernicious anaemia can be detected. Cobalamin deficiency is common due to dietary restriction or malabsorption. As severe maternal cobalamin deficiency during pregnancy and breastfeeding can lead to devastating effects on the child, universal screening of cobalamin level in pregnancy should be considered.

Keywords: Anaemia; Methylamalonic aciduria; Cobalamin; Mutation

Abbreviations:

Cbl: Cobalamin; TDS: Three Times Daily; MMA: Methylamalonic Aciduria; LSCS: Lower Segment Caesarean Section

Introduction

Methylmalonic acid serves as a metabolic intermediary in the formation of succinyl-CoA via the action of methylmalonyl-CoA mutase. This reaction requires Cobalamin (Cbl) as a cofactor. Without it, methylmalonyl-CoA mutase cannot function and the levels of methylmalonic acid in blood and urine are greatly increased. The dietary lack of Cbl has been termed ‘acquired methylmalonic aciduria’ [1]. This is in contrast to ‘classical’ methylamalonic aciduria, which is an inborn error of metabolism due to defects in either Cbl metabolism or methylamalonylmutase activity [2,3].

Cbl also plays an important role in the synthesis of methionine from homocysteine through its action as a cofactor of methionine synthase [4], and, therefore, hyperhomocysteinaemia often also occurs. Here, we present the case of an infant with methylamalonic aciduria secondary to a congenital Cbl deficiency due to maternal subclinical pernicious anaemia.

Case Report

This male infant of Russian non-consanguineous parents was born at 41 weeks gestation via an emergency section, with a birth weight of 3.8 kg. He presented aged nine weeks with hepatosplenomegaly, pallor, a reduced interest in food, and a reduced level of consciousness. His full blood count showed he was anaemic with haemoglobin of 5.5 g/dL (reference range 9.0-14.1), platelets of 69x10x9/L (reference range 152-440), and neutrophils of 0.5x10 (reference range 2.5-6.4). At this point he received a single unit of packed red blood cells and was discharged. He was readmitted one month later with pneumonia and was noted at this point to have hypogammaglobulinaemia, IgG 0.9 (reference range 2.5-6.4). At this point he received a single unit of packed red blood cells and was discharged. He was readmitted one month later with pneumonia and was noted at this point to have hypogammaglobulinaemia, IgG 0.9 (reference range 2.5-6.4), platelets of 69x10x9/L (reference range 152-440), and neutrophils of 0.5x10 (reference range 2.5-6.4). At this point he received a single unit of packed red blood cells and was discharged. He was readmitted one month later with pneumonia and was noted at this point to have hypogammaglobulinaemia, IgG 0.9 (reference range 2.5-6.4), platelets of 69x10x9/L (reference range 152-440), and neutrophils of 0.5x10 (reference range 2.5-6.4). At this point he received a single unit of packed red blood cells and was discharged. He was readmitted one month later with pneumonia and was noted at this point to have hypogammaglobulinaemia, IgG 0.9 (reference range 2.5-6.4), platelets of 69x10x9/L (reference range 152-440), and neutrophils of 0.5x10 (reference range 2.5-6.4). At this point he received a single unit of packed red blood cells and was discharged. He was readmitted one month later with pneumonia and was noted at this point to have hypogammaglobulinaemia, IgG 0.9 (reference range 2.5-6.4), platelets of 69x10x9/L (reference range 152-440), and neutrophils of 0.5x10 (reference range 2.5-6.4)
25th centile for both head circumference and weight. At this point, metabolic testing was carried out which noted a high ammonia (153 μmol/L; reference range <40), borderline high lactate of 2.8 mmol/L (0.7-2.1) and strongly raised urinary methylmalonate (3290 μmol/mol creatinine; reference range 0-30) and methylcitrate (107 μmol/mol creatinine; reference range 0-25).

At the time of diagnosis urinary methylmalonate had risen to 4280 μmol/mol creatinine and methylcitrate 179 μmol/mol creatinine

He was started on oral vitajoule 120 ml 3 hourly, L-carnitine 250 mg TDS and hydroxycobalamin 1mg IM daily. After two days of this treatment there was a marked biochemical improvement, with ammonia normalisation at 34 μmol/L (reference range <40), and urinary methylmalonic acid falling to 19 μmol/mmol creatinine (Cbl levels became >1000 ng/L; reference range 293-1210).

Prior to this admission the child had been exclusively breastfed and the parents were advised to start formula feeds. A month after starting Cbl supplementation and formula feeds full blood count showed normal haemoglobin and platelet counts but a persistently low neutrophil count (0.65x10^9/L) (reference range 2.5-6.4).

In search of a cause for the infant’s initially elevated urinary methylmalonate, cobalamin studies were done on both parents. As there was a continued clinical improvement the infant was discharged from hospital after a week’s treatment with Cbl. It was discovered at this point that his mother had low Cbl level without any dietary clues such as exclusion of B12 sources from the diet. Further investigations revealed increased plasma homocysteine level and urine methylmalonic acid. Intrinsic factor antibody levels were raised suggesting an underlying diagnosis of pernicious anaemia.

Interestingly the maternal full blood count was normal, with a haemoglobin of 12.4 g/DL (reference range 12-16 g/DL), mean corpuscular volume of 93fl (reference range 80-100fl), platelets 230x10^9/L (reference range 150-400x10^9/L), white cell count 6.9x10^9/L (reference range 4-11x10^9/L), neutrophils 3.58x10^9 (reference range 2.0-7.0x10^9/L). It was postulated that there was, therefore, an inadequate supply of Cbl provided during the course of the pregnancy and breastfeeding, resulting in the acquired methylmalonic aciduria.

The patient was followed up at routine outpatient appointments where it was noted that by nine months of age he was on the 75th centile for weight and on the 25th for height. He was fed with normal diet and the Cbl were stopped. By 17 months he was just above the 91st centile for weight and between the 75th and 50th for height. He was noted to be age appropriate for development in his personal and social interactions, and his eye and hand coordination. He was noted to have a slight delay in his use of language and gross motor development.

Immune system support was continued in the form of an intravenous immunoglobulin infusion three times weekly from the age of 5 months until he was 18 months of age. It was then noted that his IgA had normalised, and the only remaining immunoglobulin abnormality was low IgM levels at 0.21 g/L (reference range 0.5-2.2 g/L). It was felt that there was no further need to continue IVig infusions and the child has remained well 9 months after stopping the infusions and has no infections requiring antibiotics. He remains healthy at 2 years and two months of age. His IgG is slightly below the normal limit at 3.22 g/L (reference range 3.7-15.8 g/L) and his IgM levels are persistently low at 0.26 g/L (reference range 0.5-2.2 g/L).

Given the absence of any infection it was felt that this was not an indication to continue supplementation. He will continue to be monitored.

Discussion

Methylmalonic acid elevation can result from: 1) Cbl deficiency, 2) inborn errors of metabolism, or 3) renal impairment [5]. The elevated urinary methylmalonic acid coupled with haematological abnormalities the clinical and biochemical improvement made once supplementation with Cbl began makes it very likely that Cbl deficiency was the underlying cause in this case. Although it is rare to see levels of methylmalonic acid:creatinine ratios as high as 4890 μmol/I in cases where the elevation is secondary to Cbl deficiency it is important, therefore, to consider all of the possible differential diagnoses for a raised methylmalonic acid, as the degree of rise seen does not necessarily point towards any specific diagnosis [6].

Cbl deficiency of any cause is common, with a prevalence of between 50-200 people/100,000 in the UK [7]. Pregnancy is known to be associated with an increased consumption of Cbl [8], the majority of which is utilised by the placenta. Pregnancy is therefore also associated with an increased risk of Cbl deficiency [9] independent of any haemodilution.

Under normal circumstances infants will receive a store of about 20-25 μg of Cbl from their mother during gestation. This will be sufficient to last 6-8 months [10] even with a Cbl deficient diet [11]. If, for any reason, there is a reduction in maternal stores of Cbl during the course of the pregnancy then it will not be possible to pass a suitably large reserve on to the infant. Symptoms of deficiency usually appear between 4-6 months of age [12] and are most commonly secondary to exclusively breast feeding mothers with vegan or vegetarian diets or pernicious anaemia [13]. This is in contrast to those with ‘classical’ methylmalonic aciduria, who will typically present within hours to weeks of birth [3]. In mothers with reduced Cbl levels, particularly those who, themselves, remain asymptomatic, exclusively breastfeeding an infant for the first months of life can lead to the development of deficiency [14].

The typical presentation of an infant with Cbl deficiency includes failure to thrive, feeding difficulties, hypotonia, lethargy, tremors, hyperirritability, and coma [13]. With prompt treatment with supplementation of Cbl there will be a rapid improvement, and, indeed, the majority of infants with Cbl deficiency do make this recovery. However, the longer the infant is left deficient, the greater the likelihood that they will develop irreversible residual neurological damage. The majority with Cbl deficiency that are treated within 3-6 months will show a full recovery, with no further neurological sequelae [15].

The damage caused by infantile deficiency of Cbl occurs typically in the first 6 months of life, and, as such, may affect the maturation of oligodendrocytes and myelination of the brain [16]. Indeed, this can result in permanent neurological impairment.

It is possible that hypogammaglobulinaemia can occur secondary to Cbl deficiency, and, this child was more profoundly hypogammaglobulinaemic than in most children affected by transient hypogammaglobulinaemia of infancy. This apparent phenomenon has been reported before in both infants [17] and adults [18]. However, the exact mechanism remains unclear.

The key to managing infants with a high methylmalonic aciduria is a high degree of suspicion of possible Cbl deficiency, early recognition.
of the symptoms, and an appropriate intervention at the earliest possible opportunity. The risk of permanent neurological damage is greatest in those where the maternal deficiency is unknown and where there is a significant diagnostic delay [14]. It has also previously been shown that pernicious anaemia may present non-classically, or may be asymptomatic. This puts all progeny of mothers with this disease but few or no symptoms [19], as shown in this case, at an increased risk of diagnostic delay. A high index of suspicion for low maternal Cbl levels should be maintained in children presenting with Cbl responsive methylmalonic aciduria even if the mother is asymptomatic.

Given the prevalence of Cbl deficiency in pregnancy and the irreversible damage that can result from Cbl deficiency, it may be time to consider the use of screening for B12 deficiency in pregnancy or the puerperium to prevent cases similar to that described here. Both methylmalonic acid and total homocysteine are more sensitive and specific tests, with methylmalonic acid more specific than total homocysteine. It is, therefore, a poor marker for the bioavailability of Cbl [22]. With this in mind, any nascent screening programme may consider using urinary methylmalonic acid levels as either a standalone screening test or alongside the other measures of Cbl deficiency described above.

**Take Home Message**

In infants presenting with methylmalonic aciduria a high degree of suspicion about low maternal cobalamin levels should be maintained, even if the mother is asymptomatic.

**Compliance with Ethics Guidelines**

All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.

**Author Contributions**

SG collected the data and wrote the manuscript. HP, AJ, RL co-wrote and reviewed the manuscript; PG conceived the idea and reviewed the manuscript.

**References**

1. Weber-Ferro W, Hertzberg C, Röder H, Timme K, Rossi R (2011) Intact recovery from early ‘acquired methylmalonic aciduria’ secondary to maternal atrophic gastritis. ActaPaediatr 100: e138-140.
2. Desdatto F, Boenzi S, Santorelli FM, Dionisi-Vici C (2006) Methylmalonic and propionic aciduria. J Inherit Metab Dis 29: 104-112.
3. Oberholzer VG, Levin B, Burgess EA, Young WF (1967) Methylmalonic acidurias. An inborn error of metabolism leading to chronic metabolic acidosis. Arch Dis Child 42: 492-504.
4. Drennan CL, Huang S, Drummond JT, Matthews RG, Lidwיג ML (1994) How a protein binds B12: A 3.0 A X-ray structure of B12-binding domains of methionine synthase. Science 266: 1669-1674.
5. Loikas S, Koskinnen P, Irla K, Löppönen M, Isoaho R, et al. (2007) Renal impairment compromises the use of total homocysteine and methylmalonic acid but not total vitamin B12 and holotranscobalamin in screening for vitamin B12 deficiency in the aged. ClinChem Lab Med 45: 197-201.
6. Fowler B, Leonard JV, Baumgartner MR (2008) Causes of and diagnostic approach to methylmalonic acidurias. J Inherit Metab Dis 31: 350-360.
7. Stabler SP, Allen RH (2004) Vitamin B12 deficiency as a worldwide problem. Annu Rev Nutr 24: 299-326.
8. Lührby AL, Cooperman JM, Donnenfeld AM, Herrero JM, Teller DN, Wenig JB (1958) Observations of transfer of vitamin B12 from mother to fetus and newborn. Am J Dis Child 96: 532-533.
9. Metz J, McGrath K, Bennett M, Hyland K, Bottiglieri T (1995) Biochemical indices of vitamin B12 nutrition in pregnant patients with subnormal serum vitamin B12 levels. Am J Hematol 48: 251-255.
10. BAKER SJ, JACOB E, RAJAN KT, SWAMINATHAN SP (1962) Vitamin-B12 deficiency in pregnancy and the puerperium. Br Med J 1: 1658-1661.
11. McPhee AJ, Davidson GP, Leahy M, Beare T (1988) Vitamin B12 deficiency in a breast fed infant. Arch Dis Child 63: 921-923.
12. Stabler SP (2013) Clinical practice. Vitamin B12 deficiency. N Engl J Med 368: 149-160.
13. Dror DK, Allen LH (2008) Effect of vitamin B12 deficiency on neurodevelopment in infants: current knowledge and possible mechanisms. Nutr Rev 66: 250-255.
14. Honzik T, Adamovcova M, Smolova V, Magner M, Hrubá E, et al. (2010) Clinical presentation and metabolic consequences in 40 breastfed infants with nutritional vitamin B12 deficiency – what have we learned? Eur J PaedNeuro14: 488-495.
15. Sadowitz PD, Livingston A, Cavanaugh RM (1986) Developmental regression as an early manifestation of vitamin B12 deficiency. ClinPediatr (Philadelphia) 25: 369-371.
16. Bjerke-Monsen AL, Ueland PM (2011) Cobalamin status in children. J Inherit Metab Dis 34: 111-119.
17. Quentin C, Huybrechts S, Rozen L, De Laet C, Demulder A, et al. (2012) Vitamin B12 deficiency in a 9-month-old boy. Eur J Pediatr 171: 193-195.
18. Conn HO, Binder H, Burns B (1968) Pernicious anemia and immunologic deficiency. Ann Intern Med 68: 603-612.
19. Carmel R (1988) Pernicious anemia. The expected findings of very low serum cobalamin levels, anemia, and macrocytosis are often lacking. Arch Intern Med 148: 1712-1714.
20. Heileland G, Schneede J, Ueland PM, Lund PK, Refsum H, et al. (1999) Cobalamin deficiency in general practice. Assessment of the diagnostic utility and cost-benefit analysis of methylmalonic acid determination in relation to current diagnostic strategies. ClinChem 45: 189-198.
21. Bolam BJ, Solli JD, Schneede J, Grettum KA, Loraas A, et al. (2000) Evaluation of indicators of cobalamin deficiency defined as cobalamin-induced reduction in increased serum methylmalonic acid. ClinChem 46: 1744-1745.
22. Wickramasinghe SN, Fida S (1993) Correlations between holotranscobalamin II, holo-haptocorrin, and total B12 in serum samples from healthy subjects and patients. J ClinPathol 46: 537-539.